Ad
CBAY Stock Quote Trading Chart CymaBay Therapeutics Inc.
home / stock / cbay / cbay quote
Quote | CymaBay Therapeutics Inc. (NASDAQ:CBAY)
| Last: | $19.71 |
|---|---|
| Change Percent: | 0.52% |
| Open: | $19.03 |
| Close: | $19.71 |
| High: | $19.88 |
| Low: | $18.27 |
| Volume: | 3,168,592 |
| Last Trade Date Time: | 12/01/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
CBAY Last Five Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $19.71 | $19.03 | $19.71 | $19.88 | $18.27 | 3,168,592 | 12-01-2023 |
| $19.13 | $18.89 | $19.13 | $19.79 | $18.89 | 3,500,856 | 11-30-2023 |
| $18.78 | $18.01 | $18.78 | $19.02 | $17.9501 | 2,417,232 | 11-29-2023 |
| $18.03 | $18.19 | $18.03 | $18.38 | $17.47 | 2,605,135 | 11-28-2023 |
| $18.2 | $18.93 | $18.2 | $18.93 | $17.9412 | 1,726,560 | 11-27-2023 |
| $19.1 | $17.92 | $19.1 | $19.1 | $17.92 | 676,359 | 11-24-2023 |
| $17.9 | $18.26 | $17.9 | $18.4548 | $17.82 | 1,149,873 | 11-23-2023 |
| $17.9 | $18.26 | $17.9 | $18.4548 | $17.82 | 1,149,873 | 11-22-2023 |
| $18.11 | $18.55 | $18.11 | $19.06 | $17.99 | 1,581,524 | 11-21-2023 |
| $18.66 | $18.36 | $18.66 | $18.81 | $17.77 | 1,891,216 | 11-20-2023 |
| $18.36 | $18.26 | $18.36 | $18.47 | $17.97 | 1,221,248 | 11-17-2023 |
| $18.19 | $18.04 | $18.19 | $18.66 | $17.95 | 1,686,017 | 11-16-2023 |
| $18 | $17.18 | $18 | $18.55 | $16.95 | 1,795,827 | 11-15-2023 |
| $17.2 | $17.5 | $17.2 | $17.615 | $16.86 | 2,987,918 | 11-14-2023 |
| $16.87 | $15.91 | $16.87 | $16.98 | $15.5 | 1,789,730 | 11-13-2023 |
| $16.3 | $15.23 | $16.3 | $16.54 | $15.1 | 2,957,806 | 11-10-2023 |
| $14.86 | $15.73 | $14.86 | $16 | $14.2 | 2,220,479 | 11-09-2023 |
| $15.7 | $16.4 | $15.7 | $16.51 | $15.1801 | 1,422,605 | 11-08-2023 |
| $16.44 | $16.36 | $16.44 | $16.61 | $16.15 | 2,584,291 | 11-07-2023 |
| $16.44 | $16.69 | $16.44 | $16.69 | $15.99 | 2,283,801 | 11-06-2023 |
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Ad
-
2023-11-27 22:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
-
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting® PR Newswire 61.7% of patients on seladelpar 10 mg achieved the primary composite endpoint vs. 20.0% of patients on...
-
Announced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance. Seladelpar granted revised Breakthrough Therapy Designation for the treatment of PBC including pruritus in patients without ...